Votrient-400mg [ Pazopanib ] coated Novartis Tablets Uses, MRP, Cost India.
Votrient 400mg tablets are containing a functioning constituent like Pazopanib Hydrochloride; introduce as hydrochloride salt ofPazopanib Votrient 400mg tablets which is a little moiety ousts restraining movement against tyrosine kinase with hostile to malignancy impact.
Votrient is FDA endorsed item which is intense and different focused on receptors like endothelial Votrient 400mg development Votrient 400mg tablets factor receptor tyrosine kinase inhibitor causes bar of development of tumor cells and prompts angiogenesis restraint.
Active substance: Pazopanib hydrochloride
Pack: 30 tablets in a container
Classified as: Anti-neoplastic agent
Prescribing information of Votrient
Votrient tablets are majorly indicated Votrient 400mg in the conditions such as;
Metastatic renal cell carcinoma
Advanced soft tissue sarcoma
The major drawback of Votrient tablets therapy includes as;
The potency of Votrient tablets Votrient 400mg tablets are not evaluated for the therapy of adipocytic soft tissue sarcoma & gastrointestinal stromal tumors patients.
Pazopanib hydrochloride, a Votrient 400mg tablets second generation drug which is considered as multitargeted tyrosine kinase prohibitor which is dynamic against vascular Votrient 400mg endothelial development Votrient 400mg tablets factor receptor I, II, and III, platelet determined development factor alpha and beta and cKit.
Pazopanib is additionally targets angiogenesis pathway; which is basic for tumor vein development and this Votrient 400mg tablets arrangement is in charge of tumor continuance and development.
Pazopanib pharmacologically characterized as;
Tyrosine kinase prohibitor
Votrient tablets after administration, Votrient 400mg reaches maximum plasma concentration time between 2 to 4 hours.
While compared the administration of whole tablets, with crushed powder of tablet causes increased bioavailability and absorption of Pazopanib frequently.
The effect of food with Pazopanib causes elevation in systemic exposure of Pazopanib; votrient tablets should Votrient 400mg be administered at least 1 hour earlier or 2 hours after the food intake.
The human plasma protein binding Votrient 400mg tablets capacity of Pazopanib is very high nearly it reaches as 99%.
The metabolism of Pazopanib is undergoes with the help of CYP3A4 with lesser contribution of CYP1A2 & CYP2C8.
The terminal half Votrient 400mg life period of Pazopanib is 30.9 hours.
The primary elimination of Pazopanib Votrient 400mg tablets is occurs via feces; lesser in urine.
When to take the Votrient
The administration of Votrient tablets Votrient 400mg tablets should be recommended as without food.
It should be taken as 1 hour earlier or 2 hours after food intake.
Dosage regimens of Votrient
The daily recommended dose of Votrient tablets are 800mg should be taken orally as a single dose.
The dose of Votrient should not be Votrient 400mg tablets exceeded to 800mg
Votrient 400mg tablet contains 400mg of Pazopanib hydrochloride.
In renal cell cancer; the starting Votrient 400mg dose is 400mg and followed by decreasing or increasing the dose of 200mg depends upon the tolerability of the patients.
In soft tissue sarcoma, the dose should be reduced or elevates as 200mg on the basis of patients tolerability.
There is no dosage adjustment should be recommended for mild condition.
In moderated impaired patients, Votrient 400mg other than Votrient tablet should be considered; the dose of votrient should be decreased to 200mg daily.
Votrient treatment should be discontinued in case of severe hepatic impairment condition.
Concurrent use of CYP3A4 inhibitors:
This combinational therapy causes Votrient 400mg tablets elevation of Pazopanib concentration and leads to adverse.
To avoid this problem, Votrient 400mg this concomitant use should not be allowed.
If this combination of Pazopanib with Votrient 400mg tablets CYP3A4 inhibitors is necessary for the patients, the dose of Pazopanib should be reduced to 400mg and monitor the adverse effects frequently.
Concurrent use of CYP3A4 inducers:
This usage may reduce the Votrient 400mg concentration of Pazopanib, to overcome the problem avoid this concomitant use.
In case of patient is necessary for using strong CYP3A4 inducers, stop the Votrient therapy
Votrient caused side effects
The major adverse effects;
Prolongation of QT intervals
Venous & arterial Votrient 400mg tablets thromboembolic
Interstitial lung disease
Reversible posterior leukoencephalopathy syndrome
Thrombotic Votrient 400mg microangiopathy
Depletion of sodium, magnesium
Similar to renal cell cancer but some alteration may occur;
Elevation of alkaline phosphatase
Elevation of total bilirubin, potassium
Concurrent use of votrient tablet with the drugs metabolized by CYP3A4, CYP2D6 or CYP2C8 should not be Votrient 400mg allowed, this combination may causes prohibition of metabolism of these products and leads to severe effect.
Concurrent uses of Votrient tablets with simvastatin leads to elevate the levels of ALT, to avoid this problem discontinue the therapy.
Votrient absorption should be affected Votrient 400mg tablets by gastric regulators; co administration of this combination should be avoided. It should be administered with dosing intervals for avoid the problem like depletion of exposure of Pazopanib.
Votrient tablet combined with Votrient 400mg CYP3A4 inhibitors causes elevating the concentration of Pazopanib. In this condition the dose of votrient should be reduced to 400mg, in case of increased adverse effects, discontinue the therapy.
Votrient tablets are co administered with Votrient 400mg CYP3A4 inducers causes depletion of concentration of Pazopanib. Avoid this combination. In such exceptional conditions patient must require strong CYP3A4Â Votrient 400mg tablets inducers means, stop the Votrient tablet.
Pazopanib is a P-gp & BCRPÂ Votrient 400mg substrates, if Votrient tablets are combined with P-gp or BCRP inhibitors may leads to increase the exposure of Pazopanib and causes severe adverse effects. Avoid this combination therapy.
Patients should not be consuming Votrient 400mg tablets grape fruit or juice during the therapy.
This may elevates the Pazopanib levels in blood leads to increase the cardiac disorders.
While taking Votrient with food elevates its absorption and levels in the blood.
Possible contraindications
No suspected Votrient 400mg contraindications occur
Hypersensitivity reactions may occur due Votrient 400mg tablets to patients may contraindicate to the component of Votrient tablet.
Contraindicated to pregnancy and lactation
Examine by taking Votrient 400mg hepatic function test periodically
Avoid concomitant use of simvastatin
Avoid the combination with the drugs may Votrient 400mg tablets causes hepatic function abnormalities
Monitor ECG of patient regularly
Provide with alternative Votrient 400mg medicines
Stop the therapy in severe condition
Interrupt or discontinue the therapy, Votrient 400mg tablets while cardiac dysfunctions like ischemic condition, myocardial infarction etc.
Arterial thromboembolic events
Interstitial lung disease
Reversible posterior Votrient 400mg leukoencephalopathy syndrome
For all these above mentioned Votrient 400mg tablets conditions, discontinue the treatment.
Votrient should not be suggested to pregnancy and lactating women
Votrient may cause fetal damage
Votrient tablet container should be stored at 20oC & 25oC.
Protect the container from moisture, heat & light.
Do not administered the missed dose of votrient tablet; if it is less than 12 hours for the next dose
Votrient over dosage should not Votrient 400mg tablets have any antidote, if it may occurs patients should be provided with supportive measures and monitor the signs and symptoms.
Hemodialysis should not be suggested, Votrient 400mg tablets because Pazopanib is largely bounds to human plasma protein and it founds difficult to remove by hemodialysis.
